MannKind Gets FDA Clearance for Clofazimine IND Application
By Chris Wack
MannKind said the Food and Drug Administration has cleared its Investigational New Drug application for MNKD-101 Clofazimine inhalation suspension, enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial lung disease.
The company said it expects to get this study underway by end of the second quarter 2024 in the U.S., and internationally in the second half of 2024.
The study is a randomized, double-blind trial to evaluate the efficacy and safety of Clofazimine inhalation suspension when added to guideline-based therapy in adults with refractory nontuberculous mycobacterial lung disease caused by mycobacterium avium complex.
MannKind said that in 2022, there were about 122,000 patients living with nontuberculous mycobacterial in the U.S.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 29, 2024 06:35 ET (10:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?